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Abstract
Objective—The therapeutics for Bipolar Disorders (BD) is still far from adequate and new options
with improved effectiveness, safety and tolerability in a wide range of patients are necessary.
Preliminary data have suggested a role for dysfunctions targeting at the purinergic system in mood
disorders. This study aimed to evaluate the efficacy and tolerability of the purinergic agents
allopurinol and dipyridamole combined with lithium in bipolar mania.
Method—A randomized, placebo-controlled, double-blind study was performed in adult inpatients
(n=180) with a DSM-IV-TR diagnosis of bipolar disorder, current episode manic with or without
psychotic features (rapid cyclers and mixed episodes were not included). No antipsychotic agent was
used during the study. Subjects were given fixed oral doses of either allopurinol 600 mg/day (n=60),
dipyridamole 200 mg/day (n=60), or placebo (n=60) added to lithium for 4 weeks. Subjects were
rated at baseline and days 7, 14, 21 and 28 using the Young Mania Rating Scale (YMRS) as the
primary efficacy measure. The study was conducted between September 2003 and September 2006.
Results—Allopurinol resulted in greater mean reductions in YMRS scores from baseline to day 21
(p<.001) and day 28 (p=.003) compared with placebo using a linear model analysis (d=0.32, 95%
C.I. = 0.07 to 0.57). Remission rates were significantly higher for allopurinol compared to
dipyridamole and placebo (p=0.008). Lithium showed a significant antimanic efficacy even in the
placebo group. Decrease in plasma uric acid levels showed a significant positive association with
antimanic effects in the allopurinol group (p<0.001).
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Conclusion—Allopurinol is clinically effective and well-tolerated adjunctively with lithium in
manic episodes and may represent an alternative approach in the treatment of acute mania, especially
for those presenting tolerability and safety issues with antipsychotics. The present results strongly
support the involvement of the purinergic system in the pathophysiology and therapeutics of Bipolar
Disorder. Further placebo-controlled studies with allopurinol compared with standard mood-
stabilizers in mania and maintenance are warranted.
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Introduction
The therapeutics of bipolar mania remain an important challenge in psychiatry. A significant
number of patients either fail to respond to or are intolerant of the current therapeutic
options1,2. Importantly, despite the wide use of antipsychotic agents in combination with
lithium in bipolar mania, concerns about neurological adverse effects, arousal of depressive
symptoms, long-term use and lack of adherence have limited their clinical utility, which has
pointed out the need for new effective and well-tolerated approaches for this critical condition.
The involvement of purines and uric acid in mania has long been proposed3,4. Kraepelin was
the first to describe an association between manic symptoms, uric acid excretion,
hyperuricemia, and gout3. Cade also suggested a role for urate in manic behavior and used
lithium to keep uric acid more soluble, before discovering its antimanic properties4. It was
subsequently noted that remission from manic episodes temporarily coincided with an
increased excretion of uric acid5. Similarly, an enhanced purinergic turnover was shown and
proposed as a putative causative factor in the pathophysiology of mania4,6,7. Also, genetic data
have highlighted a potential role for purinergic dysfunction in the pathophysiology of bipolar
disorder and recurrent major depression8,9.
Uric acid is the end-product of purine metabolism. Purines are essential in energy metabolism
both intracellularly with ATP as the energetic currency, and in the extracellular space with
adenosine and ATP as key regulators of neurotransmission10. Adenosine is a widespread
neuromodulator that acts mostly through Adenosine-1 and -2A receptors, and caffeine exerts
its stimulating effects by blocking these receptors. According to both treatment guidelines11
and clinical expertise12, caffeine should be used sparingly if at all in bipolar disorder due to
its well-known neurovegetative and stimulating effects. In contrast, animal studies show that
adenosine agonists exert sedative, anticonvulsant, anti-aggressive, and antipsychotic-like
effects13. Despite the paucity of pharmacological agents that clearly target the brain purinergic
system (e.g. adenosine receptor agonists), two clinically available drugs, allopurinol (1,5-
dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) and dipyridamole, have been described to
regulate the brain purinergic metabolism. Allopurinol and its active metabolite oxypurinol are
inhibitors of xanthine oxidase and have been proposed to present therapeutic effects in many
pathological states by decreasing the production of uric acid, superoxide, and hydrogen
peroxide14. Dipyridamole is a potent inhibitor of nucleoside uptake by cells, and it increases
the extracellular concentrations of both endogenous and exogenous adenosine15,16.
Allopurinol has been shown to be effective as an add-on to different antipsychotic drugs in
refractory schizophrenia, mania and aggressive behavior7,17,18,19,20. Previous studies in mania
using allopurinol presented a small sample size, permitted other medications, and had a
heterogeneous sample, which may limit the interpretation of the findings. Furthermore,
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allopurinol has been widely used for the treatment of mitochondrial disorders associated with
increased oxidative stress levels14,21.
Interestingly, a number of findings suggest the presence of mitochondrial dysfunctions and
concomitant changes on oxidative stress parameters has been reported in bipolar disorder22,
23, which may indirectly indicate a potential role for allopurinol in bipolar disorder. We




Men and women, aged 18 to 65 years, who were inpatients with a current diagnosis of bipolar
I disorder, current episode manic with or without psychotic features as diagnosed by means of
the Structured Clinical Interview for Axis I DSM-IV-TR Disorders, Research Version, Patient
Version24 were eligible to participate. All subjects were studied between September 2003 and
September 2006 in Porto Alegre and Sta Maria, Brazil. Subjects were required to have a score
of greater than or equal to 22 on the Young Mania Rating Scale (YMRS) 25 at screening and
at randomization (baseline). All subjects were in good physical health as determined by medical
history, physical examination, blood laboratory values, electrocardiogram, chest x-ray,
urinalysis and toxicology. Subjects were free of comorbid substance abuse or dependence for
at least 5 weeks prior to screen and judged clinically not to be a serious suicide risk. Patients
had not taken any psychopharmacologic treatment for at least 4 weeks before admission and
had no detectable blood lithium levels when enrolled. Other exclusion criteria included rapid
cycling in the past 12 months, current mixed episode, previous history of refractoriness to
lithium, current Axis I psychiatric disorder other than bipolar disorder, or current clinically
significant abnormal laboratory tests.
The study was approved by the local institutional review board at each study site. All subjects
provided written informed consent before entry into the study.
Study Design
This 4-week, randomized, double-blind, placebo-controlled, parallel-group inpatient study
compared allopurinol, dipyridamole, and placebo added to lithium in acute mania. One hundred
and eighty patients were enrolled at two centers (Espirita Hospital of Porto Alegre [N=170];
and Federal University of Sta Maria, RGS, [n=10]). Before randomization, patients underwent
a 2- to 7- day screening period. Subjects who met enrollment criteria were randomly assigned
to allopurinol, dipyridamole, or placebo in a 1:1:1 ratio. All subjects and research staff were
blinded to randomization codes. Study medications were supplied in identical capsules
containing either 600 mg of allopurinol, 200 mg of dipyridamole, or placebo. Allopurinol and
dipyridamole were purchased from Glaxo-Smithkline and Boehringer Ingelhein, Brazil.
Patients received fixed dosing of either allopurinol (600 mg/day), dipyridamole (200 mg/day)
or placebo as add-on treatment to lithium. A dose of 600 mg/day of allopurinol and 200mg of
dipyridamole was chosen based on the safety and tolerability evaluation from our pilot
study26. Subjects unable to tolerate the fixed oral dose of allopurinol or dipyridamole were
discontinued as no dose reduction was permitted. On the same day that the study medication
was started, patients were also started on lithium 600 mg/day, and after 7 days, the dose of
lithium was increased to 900 mg/day, and then a flexible dose was applied according to plasma
levels. Plasma lithium levels were obtained at days 7, 14, and 21, and lithium doses were
adjusted accordingly to achieve a level of 0.6- 1.2 mmol/L. Concomitant use of diazepam
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(maximum 20mg/day) on an as needed basis for agitation was allowed during the 4-week study
period except for the 12 hour period before rating scales.
Assessment and Outcome Measures
Subjects were rated on a weekly basis at baseline and days 7, 14, 21 and 28. The YMRS was
the primary outcome measure and the secondary outcome measure was the Clinical Global
Impressions-Severity of Illness (CGI-S) scale. The primary efficacy variable was the reduction
of the YMRS total score from baseline to endpoint (week 4). Raters were all board certified
psychiatrists who displayed an inter-rater reliability of 0.90 for the YMRS. Clinical response
was defined as a 50% or greater decrease in the YMRS rating scale from baseline. Remitters
were those who had an end of study YMRS of 12 or less. An additional analysis examined
remitters with YMRS score of 7 or less at endpoint given that some other studies have used
this more stringent criterion. All adverse events were recorded. Switch into depression was
evaluated according to DSM-IV-TR criteria for major depressive episode.
Statistical Analyses
The central hypothesis was that allopurinol and dipyridamole would reduce manic symptoms
compared to placebo. All analysis was performed with the intent-to-treat sample in which all
patients with at least one post-treatment measure were included. The difference between
treatment groups was examined with a full factorial linear mixed model with restricted
maximum likelihood estimation in which drug and time were fixed effects. Akaike's
Information Criterion and Schwarz's Bayesian Criterion were used to determine the best fitting
covariance structure. Thus, a first order autoregressive covariance structure was used and the
intercept was included in the model. Least significant difference post hoc tests were carried
out to examine significant omnibus effects, but Bonferroni corrections were applied to adjust
for the number of weeks of active drug by the number of treatments studied. The raw p values
are reported and results following correction are noted. For significant interactions, the drugs
were compared at each time point to understand the timing of significant differences. Cohen's
d with corresponding 95% confidence intervals are reported to show the size of differences at
key comparison points. A secondary analysis was conducted with the linear mixed model
including diazepam dose as a time dependent covariate in an attempt to determine whether
additional medication influenced the drug comparisons. Additionally, psychosis was examined
as a factor potentially contributing to response. Chi-square tests were used to compare the
proportion of responders and remitters at the end of the study for each of the treatment groups.
Number needed to treat (NNT) was calculated for these categorical outcomes using the intent-
to-treat values. Demographic factors were examined across groups using analysis of variance
for continuous measures and χ2 for categorical measures. Significance was evaluated at p<.05,
two-tailed. Means and associated standard deviations are reported. SPSS 15.0.1 (SPSS Inc.,
Chicago, Ill) was used for this analysis.
Results
Patients
Two-hundred and forty-three subjects were screened yielding 180 subjects for randomization
who met DSM-IV TR criteria for bipolar I disorder, current episode manic with or without
psychotic features. Sixty-three subjects were excluded because of not meeting inclusion criteria
(n=38), patient decision (n=15), unstable medical illness (n=6), or other reason (n=4) (Figure
1). A total of 141 subjects were examined in the primary analysis, which included add-on
allopurinol (n=45), dipyridamole (n=50) or placebo (n=46). Subject's demographic and clinical
characteristics are summarized in Table 1.
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There were no statistically significant differences in any demographic or illness characteristics
between treatment groups. Mean serum lithium levels at the end of the study were similar for
the three groups (Table 2).
Completion rates for the drug groups were not significantly different from placebo (allopurinol:
38 of 45 [84%]; dipyridamole: 41 of 50 [82%]; and placebo: 31 of 46 [67%]) (χ2=4.57, df=2,
p = .10).
Efficacy—The linear mixed model for the YMRS showed a significant interaction between
time and drug (F=2.78, df=8,471.9, p=.005) as well as a significant main effect for time
(F=166.07, df=4,468.2, p<.0001). The drug main effect was not significant (F=2.20,
df=2,148.3, p=.11). Figure 2 shows the estimated marginal means following restricted
maximum likelihood estimation from the linear mixed model. At the end of the 4-week study,
improvement in manic symptoms was significantly greater for allopurinol-treated patients. Post
hoc tests show significantly lower YMRS total scores in the allopurinol group compared with
the placebo group at week 3 (p<.001) and week 4 (p=.003) (d=0.32, 95% C.I. = 0.07 to 0.57),
even after Bonferroni correction. The allopurinol group presented lower scores than the
dipyridamole group at week 3 (p=.048) and week 4 (p=.009) (d=0.29, 95% C.I. = 0.02 to 0.59).
The dipyridamole group showed no significant difference in YMRS scores from placebo at
any time point.
A linear mixed model with CGI-S severity scores showed a significant interaction between
drug and time (F=4.95, df=8,464.4, p<.001) and significant main effects for drug (F=5.76,
df=2,158.9, p=.004) and time (F=184.73, df=4,464.4, p<.001). The group receiving allopurinol
had significantly lower scores compared with the placebo group from weeks 2 through 4 (p<.
001) (week 4: d=0.44, 95% C.I. = 0.23 to 0.64) and compared with the dipyridamole group for
week 4 (p=.005) (d=0.29, 95% C.I. = 0.09 to 0.49). The dipyridamole group had lower scores
than the placebo group at weeks 2 and 3 (p<.001), but not at week 4 (p=.13).
Current psychosis was examined as an additional factor that might be contributing to changes
over time. However, the models for the YMRS and CGI-S showed no significant interactions
with psychosis (YMRS: psychosis × time, F=0.46, df=4,450.0, p=.77; psychosis × drug,
F=0.09, df=2,142.7, p=.91, psychosis × time × drug, F=0.67, df=8,450.8, p=.72) (CGI:
psychosis × time, F=0.10, df=4,446.2, p=.98; psychosis × drug, F=0.32, df=2,152.4, p=.73,
psychosis × time × drug, F=1.07, df=8,446.4, p=.38) and no significant main effects of
psychosis (YMRS: F=0.41, df=1,142.7, p=.52; CGI: F=0.64, df=1,152.4, p=.43). Thus,
psychosis status did not influence the drug effects over time. The use of diazepam over the
course of the study was examined with a linear mixed model. The dose decreased significantly
over the course of the trial (F=20.76, df=3,381.4, p<.0001), but the increases did not differ by
group (Drug: F=0.92, df=2,150.6, p=.40; Time × Drug: F=1.56, df=6,381.4, p=.16). Given the
decreases in dose, diazepam was used as a covariate in a secondary analysis of the YMRS total
score. This did not take away the significant interaction between drug and time (F=2.44,
df=8,457.2, p=.01). Intention-to-treat remission rates for which remission is counted at the last
observed timepoint were significantly different among the three groups after 28 days with a
more liberal (YMRS score <12) (p=.008) or more conservative (YMRS score <7) (p=.03)
definition of remission. The allopurinol group had a higher remission rate (YMRS score <12,
p=.002; YMRS score <7, p=.008) than the other two groups, which were not different (YMRS
score <12, p=.87; YMRS acore <7, p=.78). Intention-to-treat mania response rates were higher
in the allopurinol group, but this was not quite significant after 28 days (p=.06) (see Table 3).
The NNT for the allopurinol group compared to the placebo group was 5.2 for response rate,
3.6 for the more liberal remission rate, and 4.0 for the more conservative remission rate.
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Compared with the dipyridamole group, the NNT for the allopurinol group was 4.9 for response
rate, 3.8 for the more liberal remission rate, and 4.5 for the more conservative remission rate.
Additional models were run in the same manner as the total YMRS for the individual items to
identify specific areas for which allopurinol may be helpful to patients. All symptoms were
significantly improved over time (p<.001). Significant time by drug interactions were found
for items 1 (Elevated Mood) (F=3.52, df=8,466.0, p<.001), 2 (Increased Motor Activity or
Energy) (F=2.14, df=8,475.5, p=.03), 8 (Thought Content) (F=2.03, df=8,478.0, p=.04), and
11 (lack of Insight) (F=3.31, df=8,483.9, p=.001). At the end of the study, the allopurinol group
had significantly lower scores on elevated mood compared to placebo and significantly lower
scores on thought content and lack of insight compared with placebo and dipyridamole. A
significant main effect for drug was present for symptom 7 (Language or Thought Disorder)
(F=3.56, df=2,164.4, p=.03). This reflected generally higher scores for the dipyridamole group
compared with the allopurinol group, but these differences were stronger toward the end of the
study, not at baseline.
There was no statistically significant difference between treatment groups in the incidence rates
of clinically relevant changes in vital signs and laboratory measures, except for uric acid levels.
Uric acid levels were measured at baseline and after 3 weeks of treatment. The linear mixed
model showed a significant interaction between treatment group and time (F=21.40,
df=2,123.1, p<.001) as well as significant main effects for treatment (F=5.00, df=2,135.3, p=.
008) and time (F=29.36, df=1,123.1, p<.001). Post hoc tests showed significantly lower levels
in the allopurinol group at week 3 compared with the dipyridamole (p<.001) and placebo groups
(p<.001). Only the allopurinol group had a significant decrease in uric acid levels compared
with baseline (p<.001).
The correlation between the absolute changes in YMRS scores and uric acid levels from
baseline to endpoint was significant for the entire sample (r=.25, p=.007). The correlation was
significant for the allopurinol group (r=.39, p=.01), a trend for the placebo group (r=.31, p=.
06), but non-significant for the dipyridamole group (r=-.11, p=.52) (Figure 3). Thus,
improvement in mania was associated with decreasing uric acid levels for the lithium plus
allopurinol or placebo groups. For the entire sample, the change in uric acid level was positively
related to changes in several YMRS items: increased motor activity and energy (r=.21, p=.02),
language or thought disorder (r=.24, p=.009), thought content (r=.22, p=.02), and lack of insight
(r=.24, p=.01). Lastly, switch into depression was observed in 7.8% of subjects, with no
difference between groups (p=.09) (Table 2).
Predictors
Age, duration of illness, episodes, hospitalizations, prior medication usage, psychosis, sex, and
baseline uric acid levels were correlated to the absolute change in YMRS score. Only sex and
prior use of lithium were related to response. Women had better response rates than males (r=.
31, p<.001) and patients with prior lithium usage responded better than others (r=.20, p=.01).
For the allopurinol group alone, more hospitalizations (r=-.34, p=.04) and more episodes (r=-.
38, p=.02) were related to better response. No predictors were related to dipyridamole response.
For the lithium plus placebo group, women had better response rates than men (r=.42, p=.02).
Adverse Effects—Overall, lithium, allopurinol, and dipyridamole were well tolerated. The
most common side effects were dizziness (25%) and diarrhea (23%). The treatment groups
were not significantly different on any other side effects (Table 2). Only one patient (in the
dipyridamole) presented a severe adverse effect (skin rash).
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This is the first double-blind controlled study showing therapeutic effects of allopurinol in
bipolar mania combined with lithium monotherapy. Allopurinol was significantly more
effective than dipyridamole and placebo in reducing manic symptoms and was also well-
tolerated. Antimanic effects induced by allopurinol showed a significant association with uric
acid levels, suggesting a role for purinergic system dysfunction in mania. These data confirm
our preliminary results showing the efficacy of allopurinol combined with lithium monotherapy
in 90 manic subjects26. Subsequently, the antimanic efficacy of allopurinol as adjunct therapy
to haloperidol plus lithium was also shown19.
Double-blind studies have shown the superior efficacy of lithium compared with placebo as
monotherapy for mania, but many patients persist with manic symptoms28. First-generation
antipsychotics are still a widely used option as add-on treatment to mood stabilizers in
mania29. Despite their efficacy, concern about adverse effects with these agents (particularly
extrapyramidal symptoms and tardive dyskinesia) has limited their use with standard mood
stabilizers in bipolar mania. Also, typical antipsychotics commonly induce or worsen
depressive symptoms of bipolar disorder30. Likewise, despite a clear superiority and positive
effects over typical antipsychotics, atypical antipsychotics have also been associated with
weight gain and metabolic disturbances30. Different from second-generation antipsychotics,
allopurinol showed no weight gain or metabolic dysfunction. Finally, allopurinol was clearly
superior to placebo, but differently from some antipsychotics, separation occurred not earlier
than week 2. Given the absence of sedative effects and good tolerability, a higher dose of
allopurinol may be useful to accelerate its onset of action.
This study had important methodological strengths and limitations. This was a prospective,
placebo-controlled randomized trial and enrolled a relatively large sample of subjects with
manic episode. Also, none of the patients were treated with any typical or atypical
antipsychotics during the follow-up period, which based on their potential antimanic effects,
could produce a decreased effect size when evaluating the therapeutic effectiveness of
allopurinol and dipyridamole.
Although we used benzodiazepines in this study which could have some effects in reducing
manic symptoms, controlling for benzodiazepine use did not change our results. We excluded
patients with mixed episodes, rapid cycling and comorbidity with substance abuse (potential
factors predictive of non-response to lithium), therefore limiting the generalization of the
present data. In contrast to most of the data available on lithium efficacy in mania (mostly using
antipsychotic drugs in manic patients poorly responsive to lithium), this sample included
patients who were potential responders to lithium and, thus, the high response and remission
rates observed even in the placebo group clearly show a significant antimanic efficacy of
lithium in the absence of rapid cycling/mixed episode and/or drug use.
An additional limitation of this study was not including depression rating scales. We decided
not to include scales for measuring depression as we were specifically interested in the
antimanic effects of purinergic agents. For that reason, we also excluded patients with mixed
episodes; subjects with these features are at a greater risk of cycling into depression31. It could
be argued that although allopurinol was effective in acute manic episodes, depression
symptoms could have worsened. We did not find this to be the case; there was no difference
in the number of subjects meeting DSM-IV criteria for major depressive episode at the end of
the study. Future studies would need to include patients with these characteristics. Finally, our
findings apply only to acute mania; additional trials would need to be conducted to examine
the efficacy and safety of allopurinol during the continuation and maintenance phases of
treatment of bipolar disorder.
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The putative mechanisms involved in the therapeutic effects of allopurinol in bipolar mania
may include activation of adenosinergic activity, mostly through A14. Adenosine inhibits the
release of glutamate, dopamine and noradrenaline16. Xanthine and hypoxanthine, the
precursors of uric acid, accumulate and can be salvaged by the enzyme hypoxanthine-guanine-
phosphorybosil-transferase, producing the nucleosides adenosine, guanosine, and inosine,
which have shown to possess neuromodulatory actions, most of them inhibitory4. Similar to
diverse mood stabilizers, allopurinol has also presented anticonvulsant properties as add-on
therapy in refractory epilepsy33,34. Allopurinol also has neuroprotective effects presumably
by limiting the production of free radicals leading to a decreased activity of superoxide
dismutase14, an enzyme for which levels have been shown to increase during manic
episodes22.
Here we observed a positive association between the antimanic efficacy of allopurinol and
plasma uric acid levels and a trend in the placebo group. Previous studies have described a
direct association of elevated uric acid levels with increased locomotor activity and refractory
mania7,33. In addition, Anumonye et al5 (1968) described a direct association between
increased excretion of uric acid and remission of manic episodes. Also, lithium might exert
antimanic effects targeting the uric acid metabolism per se, which was its main indication
before used in BD. These data reinforce a role for purines in the pathophysiology and
therapeutics of mania. Dipyridamole failed to show antimanic efficacy in the present study.
One possibility for its lack of efficacy is that dipyridamole may not reliably cross the
bloodbrain- barrier34. Overall, allopurinol was shown to be an efficacious and well-tolerated
antimanic agent when combined with lithium. The present study confirmed our preliminary
data and supports the purinergic dysfunction model in mania4. Further studies with allopurinol
in acute mania and maintenance in bipolar disorder are warranted.
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Figure 1. Patient flowchart
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Fig 2. Allopurinol significantly improved manic symptoms compared to placebo and dipyridamole
groups at weeks 3 and 4
Allopurinol vs. Placebo:** p<.01, *** p<.001
Allopurinol vs. Dipyridamole:+ p<.05, ++ p<.01
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Figure 3. A positive association between the antimanic efficacy of Allopurinol and plasma uric acid
levels and a trend in the Placebo group was observed
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Table 1









Mean (SD) Mean (SD) Mean (SD)
Age 26.9 (8.3) 29.3 (9.8) 29.3 (8.5) 1.12, .33
Gender (Female) 24 (53) 28 (56) 29 (63) 0.94, .62
Duration of Illness (years) 6.1 (5.3) 7.9 (8.2) 7.9 (7.5) 1.00, .37
All mood episodes 5.5 (4.2) 4.7 (3.6) 4.7 (3.3) 0.70, .50
Previous manic episodes
(lifetime)
4.0 (3.0) 3.0 (2.6) 3.1 (2.5) 2.15, .12
Hospitalizations 3.6 (3.6) 3.2 (3.1) 3.1 (2.9) 0.27, .76
N (%) N (%) N (%) χ2, p
Family History of Mood
Disorder
(1st Degree Relatives)
19 (42) 27 (54) 24 (52) 1.49, .48
Psychosis 21 (48) 22 (45) 21 (46) 0.08, .96
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Table 3
Efficacy Measures and Treatment Characteristics
Lithium +
Characteristic Allopurinol (N=45) Dipyridamole (N=50) Placebo (N=46) F, p
Mean (SE) Mean (SE) Mean (SE)
YMRS
 Baseline 34.2 (1.4) 34.2 (1.3) 33.8 (1.4) 0.03, .96
 1 Week 22.8 (1.4) 24.7 (1.3) 21.6 (1.4) 1.38, .25
 2 Weeks 15.1 (1.4) 17.7 (1.3) 17.5 (1.4) 1.09, .34
 3 Weeks 9.3 (1.4) 13.3 (1.4) 16.4 (1.4) 6.04, .003
 4 Weeks 6.3 (1.5) 11.7 (1.4) 12.8 (1.6) 5.39, .005
CGI Severity
 Baseline 5.4 (0.2) 5.2 (0.2) 5.1 (0.2) 0.83, .84
 1 Week 4.2 (0.2) 4.3 (0.2) 4.2 (0.2) 0.30, .74
 2 Weeks 2.9 (0.2) 3.2 (0.2) 3.8 (0.2) 7.03, .001
 3 Weeks 1.8 (0.2) 2.1 (0.2) 3.0 (0.2) 13.85, <.001
 4 Weeks 1.4 (0.2) 2.0 (0.2) 2.4 (0.2) 9.06, <.001
Diazepam
 1 Week 46.7 (4.8) 50.8 (4.6) 49.1 (4.8) 0.20, .82
 2 Weeks 39.6 (4.8) 44.8 (4.6) 45.0 (4.8) 0.42, .66
 3 Weeks 28.9 (4.9) 41.2 (4.7) 45.5 (4.8) 3.12, .046
 4 Weeks 16.3 (5.1) 28.0 (4.8) 36.1 (5.0) 3.92, .02
Uric Acid
 Baseline 4.8 (0.2) 4.7 (0.2) 4.7 (0.2) 0.11, .89
 Week 4 3.3 (0.2) 4.7 (0.2) 4.4 (0.2) 16.93, <.001
Mean (SD) Mean (SD) Mean (SD)
Serum Lithium 0.98 (0.20) 0.99 (0.19) 0.95 (0.20) 0.50, .61
N (%) N (%) N (%) χ2, p
Study Completion 38 (84) 41 (82) 31 (67) 4.57, .10
Response
 3 Weeks 36 (90) 30 (70) 22 (55) 12.14, .002
 4 Weeks 35 (92) 30 (73) 23 (74) 5.33, .07
 End 37 (82) 31 (62) 29 (63) 5.56, .06
Remission
 YMRS < 12
  3 Weeks 32 (80) 28 (65) 15 (38) 15.66, .0004
  4 Weeks 34 (90) 27 (66) 20 (65) 7.52, .02
  End 37 (82) 28 (56) 25 (54) 9.71, .008
 YMRS < 7
  3 Weeks 21 (53) 14 (33) 9 (23) 8.13, .02
  4 Weeks 27 (71) 21 (51) 14 (45) 5.36, .07
  End 29 (64) 21 (42) 18 (39) 7.04, .03
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